CN112165939A - 联合疗法 - Google Patents

联合疗法 Download PDF

Info

Publication number
CN112165939A
CN112165939A CN201980034008.0A CN201980034008A CN112165939A CN 112165939 A CN112165939 A CN 112165939A CN 201980034008 A CN201980034008 A CN 201980034008A CN 112165939 A CN112165939 A CN 112165939A
Authority
CN
China
Prior art keywords
certain embodiments
pharmaceutically acceptable
radical
substituents
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980034008.0A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·P·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CN112165939A publication Critical patent/CN112165939A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980034008.0A 2018-03-21 2019-03-20 联合疗法 Pending CN112165939A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646314P 2018-03-21 2018-03-21
US62/646,314 2018-03-21
PCT/US2019/023172 WO2019183226A1 (en) 2018-03-21 2019-03-20 Combination therapy

Publications (1)

Publication Number Publication Date
CN112165939A true CN112165939A (zh) 2021-01-01

Family

ID=67988025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034008.0A Pending CN112165939A (zh) 2018-03-21 2019-03-20 联合疗法

Country Status (16)

Country Link
US (1) US20210000838A1 (https=)
EP (1) EP3768258A4 (https=)
JP (1) JP2021517116A (https=)
KR (1) KR20200135439A (https=)
CN (1) CN112165939A (https=)
AU (1) AU2019238207A1 (https=)
BR (1) BR112020019082A2 (https=)
CA (1) CA3093847A1 (https=)
EA (1) EA202092154A1 (https=)
IL (1) IL277336A (https=)
MA (1) MA52090A (https=)
MX (1) MX2020009773A (https=)
SG (1) SG11202009137PA (https=)
TW (1) TW202002983A (https=)
WO (1) WO2019183226A1 (https=)
ZA (1) ZA202005661B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020249001A1 (zh) * 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TW202112369A (zh) * 2019-06-10 2021-04-01 英屬開曼群島商百濟神州有限公司 口服膠囊劑及其製備方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215374A1 (zh) * 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
US9949971B2 (en) * 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
WO2016024227A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAM CONSTANTINE S 等: "Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin\'s Lymphoma" *

Also Published As

Publication number Publication date
EA202092154A1 (ru) 2021-03-22
AU2019238207A1 (en) 2020-10-01
MA52090A (fr) 2021-04-21
MX2020009773A (es) 2020-10-08
TW202002983A (zh) 2020-01-16
IL277336A (en) 2020-10-29
CA3093847A1 (en) 2019-09-26
EP3768258A1 (en) 2021-01-27
KR20200135439A (ko) 2020-12-02
JP2021517116A (ja) 2021-07-15
ZA202005661B (en) 2023-05-31
US20210000838A1 (en) 2021-01-07
EP3768258A4 (en) 2022-01-12
BR112020019082A2 (pt) 2020-12-29
WO2019183226A1 (en) 2019-09-26
SG11202009137PA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CN112165939A (zh) 联合疗法
ES2891734T3 (es) Derivados de bencimidazol como inhibidores de tirosina quinasa ERBB para el tratamiento del cáncer
EP3515414B1 (en) Combination therapy
US11351176B2 (en) Combination therapy
JP2023022081A (ja) 併用療法
ES2821102T3 (es) Derivados de azaquinazolincarboxamida
WO2020132563A1 (en) Combination therapy
CN112839651A (zh) 联合疗法
CN112888441A (zh) B细胞恶性肿瘤的治疗
CN115919859A (zh) 一种杂芳基衍生物的药物组合物及其在医药上的应用
EA040851B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210101